SecBot SecBot
8-K ·Filed Apr 30, 2026

SMMT

Summit Therapeutics Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001599298-26-000037
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The ASCO 2026 presentation of HARMONi-6 OS data on May 31 is the next major catalyst. The HARMONi-3 squamous interim PFS analysis did not stop early, but the final PFS readout in H2 2026 remains a key event. The PDUFA date in November 2026 provides a longer-term binary catalyst. Monitor cash burn trajectory given $598.7M in cash.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.12
T+0 close · Apr 30, 2026 · via day close
Latest settled
−22.12%
T+60 · $12.55
Vs SPY
−25.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $16.12entry
  2. T+1 · 7mo ago +5.37%α +5.71% · $16.98
  3. T+5 · 7mo ago +6.42%α +4.08% · $17.15
  4. T+20 · 6mo ago −2.51%α −7.80% · $15.71
  5. T+60 · 4mo ago −22.12%α −25.19% · $12.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Summit Therapeutics reported Q1 2026 financial results and operational progress. The company posted a GAAP net loss of $189.4M ($0.24/share), wider than the $62.9M loss in Q1 2025, driven by increased R&D and stock-based compensation. Key catalysts include the upcoming ASCO 2026 presentation of HARMONi-6 overall survival data as a late-breaking abstract and the HARMONi-3 squamous cohort final PFS data expected in H2 2026, with the PDUFA date for ivonescimab BLA set for November 14, 2026.

Key Financial Metrics

EPS
−$0.24
est −$0.33 · +27.3%
Rating
in line

Key Facts

  • GAAP net loss of $189.4M ($0.24/share) in Q1 2026 vs $62.9M ($0.09/share) in Q1 2025
  • Cash and short-term investments at $598.7M as of March 31, 2026, down from $713.4M at year-end 2025
  • HARMONi-6 overall survival data selected as late-breaking abstract for ASCO 2026 Plenary Session on May 31, 2026
  • HARMONi-3 squamous cohort interim PFS analysis completed; iDMC recommended study continue; final PFS data expected H2 2026
  • FDA PDUFA goal date for ivonescimab BLA is November 14, 2026
  • Non-GAAP net loss was $116.6M ($0.15/share) in Q1 2026 vs $51.8M ($0.07/share) in Q1 2025

Financial Impact

No revenue reported; operating cash burn of $122.3M in Q1 2026 vs $61.1M in Q1 2025

net losscash burnR&D expenses

Risk Factors

  • Clinical trial failure risk for ivonescimab in ongoing Phase III studies
  • Cash burn rate increasing; $598.7M may not be sufficient to fund all planned trials to completion
  • Regulatory risk: FDA may not approve ivonescimab by PDUFA date or may require additional data

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001599298-26-000037
Document: smmt-20260430.htm0001599298-26-000037
Document: 0001599298-26-000037-index-headers.html0001599298-26-000037
Document: 0001599298-26-000037-index.html0001599298-26-000037
Document: 0001599298-26-000037.txt0001599298-26-000037
8-K Data (Synthetic)0001599298-26-000037

Track record

24 reports on SMMT

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 18, 20263d ago 8-K Neutral 4/10 Entry $10.50 to $10.57 Now $9.95 −5.24% ▲ +0.67% +2.63% vs SPY
  2. Nov 16, 20266d ago 8-K Bearish 7/10 Entry $11.82 to $10.67 Now $9.95 +15.82% ▲ +9.73% +8.71% vs SPY
  3. Nov 4, 202617d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $9.95 −29.88% ▲ +15.08% +14.77% vs SPY
  4. Nov 4, 202617d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $9.95 −29.88% ▲ +15.08% +14.77% vs SPY
  5. Nov 4, 202617d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $9.95 −38.47% ▼ −12.24% −7.84% vs SPY
  6. Oct 21, 20264w ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $9.95 −37.14% ▼ −1.77% −0.59% vs SPY
  7. Oct 19, 20264w ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $9.95 −36.10% ▲ +3.34% +3.00% vs SPY
  8. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $9.95 −39.29% ▲ +3.17% +3.38% vs SPY
  9. Sep 15, 20269w ago 8-K Bullish 7/10 Entry $17.40 to $17.54 Now $9.95 −42.82% ▲ +0.80% +0.48% vs SPY
  10. Sep 14, 20269w ago 8-K Bullish 7/10 Entry $18.42 to $17.40 Now $9.95 −45.98% ▼ −5.54% −5.08% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Mon (26h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026